AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21460008 — intervention group
Group type: COMPARATOR
Intervention: Pentavalent antimony treatment with deferred antihelminthic therapy
Number of subjects: 90
Study 21460008 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall time to cure
Number of subjects: 90
Study 19546250 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel active metabolite (Pras‐AM) in patients weighing <60 kg
Number of subjects: 1159
Study 19546250 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel active metabolite (Pras‐AM) in patients >=75 years
Number of subjects: 1159
Study 16469323 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) therapy
Number of subjects: 83
Study 16469323 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol therapy
Number of subjects: 83
Study 16469323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 83
Study 15598121 — intervention group
Group type: EXPERIMENTAL
Intervention: Naive users
Number of subjects: 0
Study 15598121 — intervention group
Group type: EXPERIMENTAL
Intervention: Users with brief training or instructions
Number of subjects: 0
Study 11594991 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 19
Study 11594991 — intervention group
Group type: COMPARATOR
Intervention: 6‐0 vicryl
Number of subjects: 19
Study 9182082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil tablet form (250 mg)
Number of subjects: 12
Study 9182082 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil granule form (250 mg)
Number of subjects: 12
Study 9182082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (both forms)
Number of subjects: 12
Study 8314425 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 85
Study 8314425 — intervention group
Group type: COMPARATOR
Intervention: Intensified treatment
Number of subjects: 85
Study 2967185 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg o.d. for 4 weeks, then 20 mg o.d. for 4 weeks
Number of subjects: 26
Study 2967185 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 80 mg t.i.d. for 4 weeks, then 120 mg t.i.d. for 4 weeks
Number of subjects: 26
Study 31145031 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered lifestyle intervention over a 1-year period
Number of subjects: 1597
Study 31145031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1597
Study 31145031 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered lifestyle intervention in overweight or obese individuals (BMI ≥23 kg/m2)
Number of subjects: 1597
Study 31145031 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered lifestyle intervention in lean individuals (BMI <23 kg/m2)
Number of subjects: 1597
Study 30309721 — intervention group
Group type: EXPERIMENTAL
Intervention: IV elesclomol plus weekly paclitaxel
Number of subjects: 58
Study 26099162 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis Foundation Tai Chi Program
Number of subjects: 343
Study 26099162 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 343
Study 24769437 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg) each treatment day
Number of subjects: 24
Study 24769437 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater distribution of treatment (10 weeks)
Number of subjects: 24
Study 24769437 — intervention group
Group type: EXPERIMENTAL
Intervention: CIMT (60 hours)
Number of subjects: 24
Study 24769437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22060159 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage intervention
Number of subjects: 20
Study 22060159 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 20
Study 20601897 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab combined with methotrexate (MTX)
Number of subjects: 0
Study 20601897 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 0
Study 17640375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose (44% sucrose, 2 ml)
Number of subjects: 84
Study 17640375 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier
Number of subjects: 84
Study 17640375 — intervention group
Group type: COMPARATOR
Intervention: Control (sterile water, 2 ml)
Number of subjects: 84
Study 17640375 — intervention group
Group type: COMPARATOR
Intervention: Control & Pacifier
Number of subjects: 84
Study 16291712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin with placebo
Number of subjects: 17
Study 16291712 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole with placebo
Number of subjects: 17
Study 16291712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin with voriconazole
Number of subjects: 17
Study 16291712 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 17
Study 16291712 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 17
Study 16291712 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole metabolite
Number of subjects: 17
Study 12932114 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m DTPA radioaerosol lung scintigraphy (inhalation of radiotracer for 5 minutes)
Number of subjects: 10
Study 12932114 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometric lung function test
Number of subjects: 10
Study 12932114 — intervention group
Group type: EXPERIMENTAL
Intervention: Work duration correlation
Number of subjects: 10
Study 12932114 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers, n=10)
Number of subjects: 10
Study 10655928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 36
Study 10655928 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 36
Study 10655928 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 36
Study 8664521 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA and steroids (group 1)
Number of subjects: 100
Study 8664521 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA and Aza (group 2)
Number of subjects: 100
Study 2057968 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1212
Study 2057968 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 1212
Study 6401365 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy for 1 year
Number of subjects: 0
Study 6401365 — intervention group
Group type: COMPARATOR
Intervention: Oral gold (Auranofin)
Number of subjects: 0
Study 3516041 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol C2-72
Number of subjects: 92
Study 3516041 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol D-74
Number of subjects: 92
Study 3516041 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 92
Study 31924332 — intervention group
Group type: EXPERIMENTAL
Intervention: T + PLD (trabectedin 1.1 mg/m2 for 3 h; PLD 30 mg/m2 for 1.5 h, every 3 weeks)
Number of subjects: 576
Study 31924332 — intervention group
Group type: COMPARATOR
Intervention: PLD (50 mg/m2 for 1.5 h, every 4 weeks)
Number of subjects: 576
Study 31924332 — intervention group
Group type: EXPERIMENTAL
Intervention: T + PLD (for patients with BRCA1/2 mutations)
Number of subjects: 576
Study 31924332 — intervention group
Group type: COMPARATOR
Intervention: PLD (for patients with BRCA1/2 mutations)
Number of subjects: 576
Study 31924332 — intervention group
Group type: EXPERIMENTAL
Intervention: T + PLD (for patients with BRCA1/2 mutations and a 6-12 months platinum-free interval)
Number of subjects: 576
Study 31924332 — intervention group
Group type: COMPARATOR
Intervention: PLD (for patients with BRCA1/2 mutations and a 6-12 months platinum-free interval)
Number of subjects: 576
Study 31924332 — intervention group
Group type: EXPERIMENTAL
Intervention: T + PLD
Number of subjects: 576
Study 31924332 — intervention group
Group type: COMPARATOR
Intervention: PLD
Number of subjects: 576
Study 30089179 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix IOL
Number of subjects: 60
Study 30089179 — intervention group
Group type: EXPERIMENTAL
Intervention: FineVision Micro F IOL
Number of subjects: 60
Study 30089179 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS Symfony IOL
Number of subjects: 60
Study 30089179 — intervention group
Group type: EXPERIMENTAL
Intervention: All three IOLs
Number of subjects: 60
Study 30089179 — intervention group
Group type: COMPARATOR
Intervention: Trifocal IOLs vs EDOF IOL
Number of subjects: 60
Study 27658183 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) with antioxidants
Number of subjects: 61
Study 27658183 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF)
Number of subjects: 61
Study 24880643 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM) at 0.2 mg/kg bodyweight
Number of subjects: 320
Study 24880643 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin (MOX) at 0.4 mg/kg bodyweight
Number of subjects: 320
Study 24880643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IVM and MOX
Number of subjects: 320
Study 23731996 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive chromosome screening (CCS)
Number of subjects: 155
Study 23731996 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 155
Study 20153597 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial pamphlet
Number of subjects: 100
Study 20153597 — intervention group
Group type: COMPARATOR
Intervention: Prose pamphlet
Number of subjects: 100
Study 18400671 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 44
Study 18400671 — intervention group
Group type: EXPERIMENTAL
Intervention: Easwaran's Eight-Point Program (EPP)
Number of subjects: 44
Study 18400671 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 44
Study 16358301 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) at a dose of 1,000 mg/m2 given as a 36-hour continuous infusion
Number of subjects: 13
Study 16358301 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 13
Study 11782656 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue condition (muscular fatigue induced in tibialis anterior by isometric test at 70% of maximal voluntary contraction for 40 seconds)
Number of subjects: 8
Study 11782656 — intervention group
Group type: COMPARATOR
Intervention: Normal condition (no fatigue)
Number of subjects: 8
Study 9521199 — intervention group
Group type: COMPARATOR
Intervention: Double therapy (CsA [10 mg/kg/day] plus prednisone)
Number of subjects: 250
Study 9521199 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (CsA [6 mg/kg/day] plus azathioprine plus prednisone)
Number of subjects: 250
Study 9521199 — intervention group
Group type: COMPARATOR
Intervention: Double therapy
Number of subjects: 250
Study 9521199 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 250
Study 9521199 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 250
Study 8004841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 240
Study 8004841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 240
Study 8004841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 240
Study 8004841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 8004841 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (all doses combined)
Number of subjects: 240
Study 2590974 — intervention group
Group type: EXPERIMENTAL
Intervention: Schlegel's panfundoscope
Number of subjects: 0
Study 2590974 — intervention group
Group type: COMPARATOR
Intervention: Three mirror lens
Number of subjects: 0
Study 788293 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (high or low dose)
Number of subjects: 15
Study 788293 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol (1 mg daily)
Number of subjects: 15
Study 29444502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1% starch and 10% sucrose
Number of subjects: 18
Study 29444502 — intervention group
Group type: COMPARATOR
Intervention: 10% sucrose
Number of subjects: 18
Study 27533335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose, swaddling, and vibration (using a handheld battery-powered vibrator, Hz = 92)
Number of subjects: 56
Study 27533335 — intervention group
Group type: COMPARATOR
Intervention: Sucrose and swaddling
Number of subjects: 56
Study 27533335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose, swaddling, and vibration
Number of subjects: 56
Study 23893098 — intervention group
Group type: EXPERIMENTAL
Intervention: Project SEARCH plus ASD Supports (treatment group)
Number of subjects: 40
Study 23893098 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study 22399630 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC5) on day 1 with escalating oral topotecan (3.0 mg/m² starting dose) on days 1, 8, and 15, every 4 weeks
Number of subjects: 18
Study 22399630 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC5) with oral topotecan
Number of subjects: 18
Study 20592644 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for adjusting doses of HIV-1 protease inhibitors (PIs)
Number of subjects: 0
Study 20592644 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 18179469 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban children
Number of subjects: 534
Study 18179469 — intervention group
Group type: COMPARATOR
Intervention: Rural children
Number of subjects: 534
Study 18179469 — intervention group
Group type: COMPARATOR
Intervention: Rural/urban dwelling
Number of subjects: 534
Study 15913800 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week ribavirin (RIB) administration followed by 24-week combination treatment with interferon (IFN) and RIB (Group A)
Number of subjects: 81
Study 15913800 — intervention group
Group type: COMPARATOR
Intervention: 24-week combination treatment with interferon (IFN) and ribavirin (RIB) only (Group B)
Number of subjects: 81
Study 12806908 — intervention group
Group type: EXPERIMENTAL
Intervention: Logotherapy (added to loxoprofen sodium treatment)
Number of subjects: 21
Study 12806908 — intervention group
Group type: COMPARATOR
Intervention: Loxoprofen sodium (NSAID) only
Number of subjects: 21
Study 9926970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg i.v. every 3 weeks for a maximum of six cycles
Number of subjects: 70
Study 9926970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg i.v. every 3 weeks for a maximum of six cycles
Number of subjects: 70
Study 9926970 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 70
Study 7489963 — intervention group
Group type: EXPERIMENTAL
Intervention: dDAVP, 0.5 microgram/kg
Number of subjects: 9
Study 7489963 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study 2178523 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 0
Study 2178523 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (premedication)
Number of subjects: 0
Study 2178523 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 0
Study 2178523 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 0
Study 111876 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate (Opticrom)
Number of subjects: 20
Study 111876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29795123 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation-planning
Number of subjects: 60
Study 29795123 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care diet advice
Number of subjects: 60
Study 26853244 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy, noise cancelling earplugs, and eye mask
Number of subjects: 64
Study 26853244 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 25234603 — intervention group
Group type: EXPERIMENTAL
Intervention: ECI‐guided ablation
Number of subjects: 101
Study 25234603 — intervention group
Group type: COMPARATOR
Intervention: Control (non‐ECI‐guided ablation)
Number of subjects: 101
Study 22790795 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi intervention
Number of subjects: 39
Study 22790795 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 39
Study 21465722 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced family planning outreach program
Number of subjects: 11
Study 21465722 — intervention group
Group type: COMPARATOR
Intervention: Standard services (control)
Number of subjects: 11
Study 17372126 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (2.5 mg daily) and vitamin D2 (1,000 IU)
Number of subjects: 121
Study 17372126 — intervention group
Group type: COMPARATOR
Intervention: Placebo and vitamin D2 (1,000 IU)
Number of subjects: 121
Study 16129914 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 45
Study 16129914 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 45
Study 16129914 — intervention group
Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 45
Study 16129914 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Methylprednisolone, Pentoxifylline, Saline)
Number of subjects: 45
Study 12114036 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536
Study 10566368 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interviews
Number of subjects: 0
Study 10566368 — intervention group
Group type: COMPARATOR
Intervention: Touchscreen assessments
Number of subjects: 0
Study 8607737 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual Speed test
Number of subjects: 38
Study 8607737 — intervention group
Group type: EXPERIMENTAL
Intervention: Time Estimation task
Number of subjects: 38
Study 8607737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking-Reaction dual task
Number of subjects: 38
Study 8607737 — intervention group
Group type: EXPERIMENTAL
Intervention: WAIS Symbol-Digit Substitution subtest
Number of subjects: 38
Study 1783036 — intervention group
Group type: EXPERIMENTAL
Intervention: Target selection of a long vertical bar with short vertical bars on either side having opposite disparities.
Number of subjects: 2
Study 1783036 — intervention group
Group type: COMPARATOR
Intervention: Fixation of the long vertical bar while stabilizing the configuration.
Number of subjects: 2
Study 6168848 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (600 mg/day)
Number of subjects: 12
Study 6168848 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine (600-1000 mg/day)
Number of subjects: 12
Study 6168848 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide plus Mexiletine
Number of subjects: 12
Study 6168848 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 30511293 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of peony (TGP)
Number of subjects: 211
Study 30511293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 28483330 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior RARP
Number of subjects: 120
Study 28483330 — intervention group
Group type: COMPARATOR
Intervention: Anterior RARP
Number of subjects: 120
Study 25388643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection hyaluronic acid (IAHA) for 4 weeks
Number of subjects: 150
Study 25388643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucosamine sulfate (GS) for 12 weeks
Number of subjects: 150
Study 25388643 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 150
Study 25388643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection hyaluronic acid (IAHA)
Number of subjects: 150
Study 25064093 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme (motor training and cognitive-behavioural therapy)
Number of subjects: 20
Study 25064093 — intervention group
Group type: COMPARATOR
Intervention: Usual-care alone (control group)
Number of subjects: 20
Study 22760571 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion-controlled video games (MC)
Number of subjects: 120
Study 22760571 — intervention group
Group type: COMPARATOR
Intervention: Television watching
Number of subjects: 120
Study 22760571 — intervention group
Group type: COMPARATOR
Intervention: Traditional video games (VG)
Number of subjects: 120
Study 19641052 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 218
Study 19641052 — intervention group
Group type: COMPARATOR
Intervention: La Premiere LM
Number of subjects: 218
Study 17662095 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% and lidocaine 2% mixture (group 1)
Number of subjects: 105
Study 17662095 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.75% (group 2)
Number of subjects: 105
Study 17662095 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% (group 3)
Number of subjects: 105
Study 17662095 — intervention group
Group type: EXPERIMENTAL
Intervention: All agents (group 1, group 2, group 3)
Number of subjects: 105
Study 15787921 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.2% (1 ml x kg(‐1))
Number of subjects: 182
Study 15787921 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2% (1 ml x kg(‐1))
Number of subjects: 182
Study 15787921 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.2% (1 ml x kg(‐1))
Number of subjects: 182
Study 15787921 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine and levobupivacaine
Number of subjects: 182
Study 11923128 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy with sequential paclitaxel and doxorubicin-based combination chemotherapy
Number of subjects: 100
Study 11923128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology from mastectomy specimens
Number of subjects: 100